Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research 4: Preclinical Modeling of Emerging Immunotherapy Approaches

Systemic anti-HGF monoclonal antibody therapy induces regression of intracranial glioma xenograft

K. Jin Kim, Lihong Wang, Yi-Chi Su, G. Yancey Gillespie, Amandeep Salhotra, Bachchu Lal and John Laterra
K. Jin Kim
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihong Wang
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Chi Su
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Yancey Gillespie
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amandeep Salhotra
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bachchu Lal
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Laterra
Galaxy Biotech, LLC, Mountain View, CA, University of Alabama at Birmingham, Birmingham, AL, The Kennedy Krieger Research Institute and the Johns Hoplins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

1167

Hepatocyte growth factor (HGF) and its receptor Met are involved in the initiation, progression and metastasis of numerous systemic and CNS tumors. Thus, an anti-HGF monoclonal antibody (mAb) capable of blocking the HGF-Met interaction could have broad applicability in cancer therapy. An anti-HGF mAb L2G7 that blocks binding of HGF to Met was generated by hybridoma technology, and its ability to inhibit various biological activities of HGF was measured by in vitro assays. MAb L2G7 strongly inhibited biological activities of HGF measured in vitro, including cell proliferation, and cell scattering. The ability of L2G7 to inhibit growth of tumors was determined by establishing subcutaneous and intracranial xenografts of human U87 and U118 glioma cell lines in nude mice, and treating with 50-100 μg L2G7 or control administered intraperitoneally twice per week. Treatment with L2G7 completely inhibited growth of established subcutaneous xenografts in nude mice. Moreover, systemic administration of L2G7 from Day 5 induced regression of intracranial U87 xenografts and dramatically prolonged survival of tumor-bearing mice from a median of 39 days to over 90 days. L2G7 treatment of large intracranial tumors (average tumor size, 26.7 mm3) from Day 18 induced substantial tumor regression (control group, 134.3 mm3; L2G7 treated group, 11.7 mm3) by Day 29 and again prolonged animal survival.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Systemic anti-HGF monoclonal antibody therapy induces regression of intracranial glioma xenograft
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Systemic anti-HGF monoclonal antibody therapy induces regression of intracranial glioma xenograft
K. Jin Kim, Lihong Wang, Yi-Chi Su, G. Yancey Gillespie, Amandeep Salhotra, Bachchu Lal and John Laterra
Cancer Res April 15 2006 (66) (8 Supplement) 276;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Systemic anti-HGF monoclonal antibody therapy induces regression of intracranial glioma xenograft
K. Jin Kim, Lihong Wang, Yi-Chi Su, G. Yancey Gillespie, Amandeep Salhotra, Bachchu Lal and John Laterra
Cancer Res April 15 2006 (66) (8 Supplement) 276;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • CD37 directed single chain Fv-Ig demonstrates promising preclinical activity against non-Hodgkin’s lymphoma and chronic lymphocytic leukemia
  • Spontaneous murine mammary tumours demonstrate a range of sensitivities to adoptively transferred T cells: defining the molecular and histological determinants of regression versus progression
  • Immunization of Lewis rats with a prostate cancer xenoantigen elicits predominantly xenoantigen epitope-specific T cell responses
Show more Clinical Research 4: Preclinical Modeling of Emerging Immunotherapy Approaches
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement